Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study

Baron, S.; Turck, D.; Leplat, C.; Merle, V.; Gower-Rousseau, C.; Marti, R.; Yzet, T.; Lerebours, E.; Dupas, J-L.; Debeugny, S.; Solomez, J-L.; Cortot, A.; Colombel, J-F.
March 2005
Gut;Mar2005, Vol. 54 Issue 3, p357
Academic Journal
Background: Environmental exposures in early life have been implicated in the aetiology of inflammatory bowel disease. Objective: To examine environmental risk factors prior to the development of inflammatory bowel disease in a paediatric population based case control study. Methods: A total of 222 incident cases of Crohn's disease and 60 incident cases of ulcerative colitis occurring before 17 years of age between January 1988 and December 1997 were matched with one control subject by sex, age, and geographical location. We recorded 140 study variables in a questionnaire that covered familial history of inflammatory bowel disease, events during the perinatal period, infant and child diet, vaccinations and childhood diseases, household amenities, and the family's socioeconomic status. Results: In a multivariate model, familial history of inflammatory bowel disease (odds ratio (OR) 4.3 (95% confidence interval 2.3-8)), breast feeding (OR 2.1 (1 .3-3.4)), bacille Calmette-Guerin vaccination (OR 3.6 (1.1-11.9)), and history of eczema (OR 2.1 (1-4.5)) were significant risk factors for Crohn's disease whereas regular drinking of tap water was a protective factor (OR 0.56 (0.3-1)). Familial history of inflammatory bowel disease (OR 12.5 (2.2-71.4)), disease during pregnancy (OR 8.9 (1.5-52)), and bedroom sharing (OR 7.1 (1.9-27.4)) were risk factors for ulcerative colitis whereas appendicectomy was a protective factor (OR 0.06 (0.01-0.36)). Conclusions: White family history and appendicectomy are known risk factors, changes in risk based on domestic promiscuity, certain vaccinations, and dietary factors may provide new aetiological clues.


Related Articles

  • Growth Impairment in Inflammatory Bowel Disease. Sherlock, Mary; Griffiths, Anne M. // Current Medical Literature: Growth, Growth Hormone, & Metabolism;2008, Vol. 2 Issue 2, p41 

    The article presents information on the prevalence of growth impairment in pediatric inflammatory bowel disease (IBD). It explores the patterns of growth and pubertal progression in young patients with IBD. It explains the standardized monitoring and assessment of growth. It discusses the...

  • Gastroenteric Inflammation in Children with Ulcerative Colitis. Kaufman, Stuart S.; Vanderhoof, Jon A.; Young, Rosemary; Perry, Deborah; Raynor, Stephen C.; Mack, David R. // American Journal of Gastroenterology;Jul1997, Vol. 92 Issue 7, p1209 

    This is a retrospective review of five pediatric cases of inflammatory bowel disease with gastroduodenal as well as pancolonic inflammation. The presumptive diagnosis was Crohn's disease in all. Three of five also had microscopic ileitis. Chronic active gastritis was present at diagnosis in all...

  • RESEARCH.  // Practice Nurse;1/16/2004, Vol. 27 Issue 1, p9 

    Focuses on a study which found that many children with inflammatory bowel disease (IBD) in Great Britain and Ireland are diagnosed only after prolonged delays. Highlights of a survey of hospital doctors on childhood IBD diagnoses; Ways to reduce delays of diagnosis.

  • DLG5 R30Q Variant Is a Female-Specific Protective Factor in Pediatric Onset Crohn's Disease. Biank, Vincent; Friedrichs, Frauke; Babusukumar, Umesh; Tao Wang; Stoll, Monika; Broeckel, Ulrich; Kugathasan, Subra // American Journal of Gastroenterology;Feb2007, Vol. 102 Issue 2, p391 

    OBJECTIVE: A significant association between the DLG5 variant (R30Q) and inflammatory bowel disease (IBD) has been confirmed in several independent adult IBD cohorts. There is growing evidence that gender significantly influences R30Q susceptibility in Crohn's disease (CD). Pediatric onset CD...

  • Role of alkaline phosphatase in colitis in man and rats. A Tuin // Gut;Mar2009, Vol. 58 Issue 3, p379 

    BACKGROUND AND AIMS: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic multifactorial inflammatory bowel diseases (IBDs) with unknown aetiology, but a deregulated mucosal immune response to gut-derived bacterial antigens is thought to be involved. Toll-like receptor ligands,...

  • Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort. R K Weersma // Gut;Mar2009, Vol. 58 Issue 3, p388 

    BACKGROUND: Crohn’s disease and ulcerative colitis have a complex genetic background. We assessed the risk for both the development and severity of the disease by combining information from genetic variants associated with inflammatory bowel disease (IBD). METHODS: We studied 2804...

  • Dysbiosis in inflammatory bowel disease. Tamboli C P; Neut C; Desreumaux P; Colombel J F // Gut;Jan2004, Vol. 53 Issue 1, p1 

    Abundant data have incriminated intestinal bacteria in the initiation and amplification stages of inflammatory bowel diseases. However, the precise role of intestinal bacteria remains elusive. One theory has suggested a breakdown in the balance between putative species of "protective" versus...

  • Inflammatory Bowel Disease in Kuwait. Al-Nakib, B.; Radhakrishnan, S.; Jacob, G. S.; Al-Liddawi, H.; Al-Ruwaih, A. // American Journal of Gastroenterology;Mar1984, Vol. 79 Issue 3, p191 

    Inflammatory bowel disease is considered to be rare or nonexistent in some Arab countries. During a period of 6 years, 91 patients with ulcerative colitis and 17 with Crohn's disease were seen for initial diagnosis in the Gastroenterology Department of Amiri Hospital, which serves 55% of the...

  • A Review of Immune Modifier Therapy for Inflammatory Bowel Disease: Azathioprine, 6-Mercaptopurine, Cyclosporine, and Methotrexate. Sandborn, William J. // American Journal of Gastroenterology;Mar1996, Vol. 91 Issue 3, p423 

    Presents a review of immune modifier therapy in patients with inflammatory bowel disease (IBD). Pharmacology of azathioprine (AZA), 6-mercaptopurine (6MP), cyclosporine (CYA) and methotrexate (MTX); Result of controlled trials of 6MP and AZA in patients with Crohn's disease; Categories of side...


Read the Article


Sign out of this library

Other Topics